Non-HDL and LDL cholesterol, but not calculated remnant cholesterol, are associated with subclinical atherosclerosis.

IF 4.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Malin Mickelsson, Per Liv, Kristina Stefansson, Kim Ekblom, Anders Själander, Emma Nyman, Christer Grönlund, Ulf Näslund, Johan Hultdin
{"title":"Non-HDL and LDL cholesterol, but not calculated remnant cholesterol, are associated with subclinical atherosclerosis.","authors":"Malin Mickelsson, Per Liv, Kristina Stefansson, Kim Ekblom, Anders Själander, Emma Nyman, Christer Grönlund, Ulf Näslund, Johan Hultdin","doi":"10.1016/j.jacl.2025.08.014","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Elevated low-density lipoprotein (LDL) cholesterol levels represent a significant modifiable risk factor for atherosclerotic cardiovascular disease. However, a residual risk persists, possibly attributed to other atherogenic lipoproteins such as non-high-density lipoprotein (non-HDL) and remnant cholesterol. Nevertheless, few studies have explored the independent associations between these lipid biomarkers and early atherosclerotic disease.</p><p><strong>Objective: </strong>To evaluate the relative contributions of LDL, non-HDL, and remnant cholesterol to subclinical atherosclerosis, assessed by carotid ultrasonography.</p><p><strong>Method: </strong>In this cross-sectional study, we included 1929 previously healthy individuals from the pragmatic VIPVIZA trial who had available lipid levels and carotid ultrasonography results to assess subclinical disease. Non-HDL, LDL, and remnant cholesterol were calculated from a standard lipid profile. Subclinical atherosclerosis was assessed by carotid intima-media thickness (cIMT) and the presence of carotid plaques.</p><p><strong>Results: </strong>We found that all lipid variables (LDL, non-HDL, and remnant cholesterol) were associated with subclinical atherosclerosis in univariable models (P < .01 across all models for cIMT and P < .001, P < .001, P = .003 respectively for carotid plaques). In multivariable-adjusted models, increasing LDL and non-HDL cholesterol levels were still significantly associated with increased odds of having carotid plaques (P < .001 for both) and increased cIMT (P < .001 for both). However, no independent association between remnant cholesterol and subclinical atherosclerosis was observed in the model adjusted for LDL cholesterol levels (P = .073 for cIMT and = .818 for plaque).</p><p><strong>Conclusion: </strong>Increasing LDL and non-HDL cholesterol levels, but not remnant cholesterol, seem to contribute to carotid subclinical atherosclerosis.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jacl.2025.08.014","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Elevated low-density lipoprotein (LDL) cholesterol levels represent a significant modifiable risk factor for atherosclerotic cardiovascular disease. However, a residual risk persists, possibly attributed to other atherogenic lipoproteins such as non-high-density lipoprotein (non-HDL) and remnant cholesterol. Nevertheless, few studies have explored the independent associations between these lipid biomarkers and early atherosclerotic disease.

Objective: To evaluate the relative contributions of LDL, non-HDL, and remnant cholesterol to subclinical atherosclerosis, assessed by carotid ultrasonography.

Method: In this cross-sectional study, we included 1929 previously healthy individuals from the pragmatic VIPVIZA trial who had available lipid levels and carotid ultrasonography results to assess subclinical disease. Non-HDL, LDL, and remnant cholesterol were calculated from a standard lipid profile. Subclinical atherosclerosis was assessed by carotid intima-media thickness (cIMT) and the presence of carotid plaques.

Results: We found that all lipid variables (LDL, non-HDL, and remnant cholesterol) were associated with subclinical atherosclerosis in univariable models (P < .01 across all models for cIMT and P < .001, P < .001, P = .003 respectively for carotid plaques). In multivariable-adjusted models, increasing LDL and non-HDL cholesterol levels were still significantly associated with increased odds of having carotid plaques (P < .001 for both) and increased cIMT (P < .001 for both). However, no independent association between remnant cholesterol and subclinical atherosclerosis was observed in the model adjusted for LDL cholesterol levels (P = .073 for cIMT and = .818 for plaque).

Conclusion: Increasing LDL and non-HDL cholesterol levels, but not remnant cholesterol, seem to contribute to carotid subclinical atherosclerosis.

非高密度脂蛋白和低密度脂蛋白胆固醇,但不计算残余胆固醇,与亚临床动脉粥样硬化相关。
背景:低密度脂蛋白(LDL)胆固醇水平升高是动脉粥样硬化性心血管疾病的重要可改变危险因素。然而,残余风险仍然存在,可能归因于其他致动脉粥样硬化脂蛋白,如非高密度脂蛋白(non-HDL)和残余胆固醇。然而,很少有研究探索这些脂质生物标志物与早期动脉粥样硬化疾病之间的独立关联。目的:通过颈动脉超声评价低密度脂蛋白、非高密度脂蛋白和残余胆固醇在亚临床动脉粥样硬化中的相对作用。方法:在这项横断面研究中,我们纳入了1929名来自实用VIPVIZA试验的健康个体,他们有可用的脂质水平和颈动脉超声结果来评估亚临床疾病。非高密度脂蛋白、低密度脂蛋白和残余胆固醇根据标准脂质谱计算。通过颈动脉内膜-中膜厚度(cIMT)和颈动脉斑块的存在来评估亚临床动脉粥样硬化。结果:我们发现,在单变量模型中,所有脂质变量(LDL、非hdl和残余胆固醇)都与亚临床动脉粥样硬化相关(cIMT所有模型的P < 0.01,颈动脉斑块的P < 0.001, P < 0.001, P = 0.003)。在多变量调整模型中,LDL和非hdl胆固醇水平升高仍与颈动脉斑块发生率增加(两者均P < 0.001)和cIMT升高(两者均P < 0.001)显著相关。然而,在调整LDL胆固醇水平的模型中,未观察到残余胆固醇与亚临床动脉粥样硬化之间的独立关联(cIMT的P = 0.073,斑块的P = 0.818)。结论:低密度脂蛋白和非高密度脂蛋白胆固醇水平升高,而不是残余胆固醇,似乎有助于颈动脉亚临床动脉粥样硬化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.00
自引率
6.80%
发文量
209
审稿时长
49 days
期刊介绍: Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. Sections of Journal of clinical lipidology will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信